Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $27.11

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have received an average rating of “Moderate Buy” from the eighteen research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $27.1111.

NTLA has been the topic of a number of recent research reports. Chardan Capital dropped their target price on Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. HC Wainwright reduced their target price on shares of Intellia Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a report on Friday, August 8th. Royal Bank Of Canada decreased their target price on shares of Intellia Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. Canaccord Genuity Group cut their price target on Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating on the stock in a research report on Tuesday, June 3rd. Finally, Wedbush reiterated a “neutral” rating and set a $7.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 16th.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $12.27 on Friday. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -2.62 and a beta of 2.28. The stock’s fifty day moving average price is $11.67 and its 200 day moving average price is $9.63. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $23.76.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.04. The company had revenue of $14.25 million during the quarter, compared to analysts’ expectations of $12.26 million. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The firm’s revenue was up 104.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.52) EPS. Research analysts expect that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In other news, EVP Edward J. Dulac III sold 7,462 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the sale, the executive vice president owned 106,062 shares of the company’s stock, valued at $1,486,989.24. This trade represents a 6.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director William J. Chase bought 100,000 shares of the business’s stock in a transaction dated Wednesday, August 20th. The shares were purchased at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the completion of the acquisition, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. This represents a 288.24% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 12,534 shares of company stock worth $153,837. Insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors have recently modified their holdings of the business. Northern Trust Corp increased its stake in shares of Intellia Therapeutics by 13.0% in the 4th quarter. Northern Trust Corp now owns 979,137 shares of the company’s stock valued at $11,417,000 after purchasing an additional 112,847 shares in the last quarter. Deutsche Bank AG increased its position in shares of Intellia Therapeutics by 12.1% in the fourth quarter. Deutsche Bank AG now owns 252,501 shares of the company’s stock valued at $2,944,000 after buying an additional 27,282 shares in the last quarter. Ensign Peak Advisors Inc raised its stake in shares of Intellia Therapeutics by 2.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock worth $457,000 after buying an additional 1,100 shares during the period. Lazard Asset Management LLC raised its stake in shares of Intellia Therapeutics by 7.3% during the 4th quarter. Lazard Asset Management LLC now owns 109,500 shares of the company’s stock worth $1,276,000 after buying an additional 7,488 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Intellia Therapeutics by 7.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 227,255 shares of the company’s stock valued at $2,647,000 after acquiring an additional 15,888 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.